Partnership brings reliable access to a critical cancer therapy isotope to one of the world's largest and fastest-growing oncology markets March 26, 2026 -- SHINE Technologies, LLC today announced a supply agreement with C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, establishing C-Ray as SHINE's exclusive distribution partner for non-carrier-added lutetium-177 (n.c.a. Lu-177) across mainland China, excluding certain pre-existing SHINE partnerships. Under the agreemen

March 24, 2026 -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known as MSD outside the US and Canada, to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient’s somatic genomics platform technology. Somatic genetic mutations naturally accumulate over a lifetime, resulting in trillions of different genomes within an individual.

The new alliance has launched a multi-agent AI framework to support faster, data-driven decisions in cancer research. Agentic AI system achieves 15x faster insights with over 90% accuracy. March 19, 2026--Globant (NYSE: GLOB), a digitally native company that helps organizations thrive in a digital and AI-powered future, and PharmaMar, world leader in the discovery, development and commercialization of marine-derived anti-cancer drugs, today announced a new collaboration designed to speed up can

March 17, 2026 -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, today announced a strategic manufacturing collaboration to support gene therapy programs using Apertura's TfR1 CapX, a novel AAV capsid that targets human Transferrin Receptor 1 (hTfR1) to cross the blood-

Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products March 16, 2026-- Sentynl Therapeutics Inc. (" Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (" Zydus"), announced that it is entering into an agreement with PRG S&T, a Korean company specializing in the development of medicine for rare genetic diseases, to license it

Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP). The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- and middle-income countries. The new arrangement builds upon the existing licence and manufacturing partnership between the

— Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI — March 12, 2026 -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane p

Thursday March 12, 2026 – Omios Biologics, a biotechnology company revolutionizing cancer treatment through next-generation oncolytic virus immunotherapies and systemic gene delivery platforms, today announced the signing of a Material Transfer Agreement with the Beckman Research Institute of City of Hope. Under the agreement, City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, will conduct advanced studies to further characteri

March 10, 2026 / Today Technomark Life Sciences and MAX BioPharma announced their collaboration in the development of MAX BioPharma's oxysterol drug candidate, Oxy210, for targeting metabolic dysfunction-associated steatohepatitis (MASH). As a strategic lead investor, Technomark is investing in MAX BioPharma by participating in its $13 million Series A raise to initiate and complete a Phase 1a/1b first-in-human study and invites aligned investors from the industry to join this opportunity. "We

March 09, 2026 -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital (“MGH”) for the design of a Phase 2 clinical trial eval